Publications by authors named "Chau Tran Minh Pham"
Efficacy and Tolerance of First-Line Afatinib in Elderly NSCLC Patients with EGFR Mutations in Vietnam: A Multicenter Real-World Study.
Tu Anh Do Hoa Thi Thai Nguyen Phuong Cam Pham Khoi Tuan Nguyen Thu Thi Anh Hoang Luan Van Pham Thai Van Pham Chau Tran Minh Pham
Asian Pac J Cancer Prev
October 2024
Article Synopsis
- Afatinib is an effective EGFR tyrosine kinase treatment for elderly patients with non-small-cell lung cancer (NSCLC) and EGFR mutations, but dosage adjustments are often needed due to unique health considerations.
- A retrospective analysis was conducted on 135 patients over 65, assessing treatment outcomes like time to treatment failure and overall survival using specific statistical methods.
- Findings revealed a median overall survival of 32.9 months, with certain factors (poor performance status, smoking, and uncommon mutations) linked to decreased survival rates among patients.